University of Edinburgh



AbstractCardiac biomarkers can be helpful in differentiating cardiac from non-cardiac disease in dyspnoeic patients, in detecting occult heart disease and in determining prognosis in patients with both cardiac and some non-cardiac diseases. Cardiac troponin I and N-terminal proB-type natriuretic peptide are the most widely used in clinical practice and can easily be measured from a blood sample. However, there are limitations in their use and appropriate interpretation of results is important. This article will discuss the physiology of these biomarkers and the evidence available for their use in dogs and cats. IntroductionBiological markers (biomarkers) have been defined by the Biomarkers Definitions Working Group (2001), as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”. Biomarkers are widely used in medicine and veterinary medicine to aid in diagnosis, prognostication and monitoring of therapeutic intervention. A good biomarker will be specific to the organ and/or disease process and should be quantifiable, with a change in magnitude proportional to disease severity. In theory, biomarkers can include physical examination findings, such as heart rate and respiratory rate, as well as blood and tissue-based markers. In this review, we will focus on cardiac biomarkers that can be measured in blood. Use of cardiac biomarkers in veterinary practice has only recently become commonplace, compared to more routinely measured biochemical parameters. The two commercially available cardiac biomarkers, and the ones which will be discussed further in this article, are the natriuretic peptides and cardiac troponins. This article aims to briefly describe the physiology of both of these biomarkers, and to guide the reader on their use and interpretation based on recent literature. Natriuretic PeptidesPhysiology The natriuretic peptides share a central 17 amino acid loop, with a variable carboxyl terminal (C-terminal) and amine terminal (N-terminal) (Pro?ek and Ettinger, 2010). There are several forms of natriuretic peptide; BNP (brain or B-type natriuretic peptide) and ANP (atrial natriuretic peptide) are the most clinically relevant in dogs and cats. BNP is produced by both atrial and ventricular myocytes and its synthesis and release is increased in response to myocardial stress caused by volume overload, pressure overload or ischaemia (Nakagawa et al. 1995; Biondo et al. 2003; Goetze et al. 2004). The ventricles become the main source of BNP production in disease. Stored ANP is released from granules in the atrial myocytes when the atria are stretched (Ledsome et al. 1985), but can also be released from the ventricles in disease. Secretion of both ANP and BNP can also be stimulated neurohormonally by angiotension II, endothelin and catecholamines (Erne et al. 1987; Fu et al. 1992). CNP (C-type natriuretic peptide) is released from the endothelium and acts through the NPR-B receptor to cause vasodilation. DNP (dendroaspis natriuretic peptide) is released in the venom of the green mamba snake and VNP (ventricular natriuretic peptide) is produced by primitive myocytes, mainly in fish. Urodilatin is a natriuretic peptide produced by the distal renal tubule (Pro?ek and Ettinger, 2010). The natriuretic peptides are formed as preprohormones and are processed to prohormones. Once released, proANP and proBNP are quickly cleaved to an active C-terminal (C-BNP, C-ANP) and inactive N-terminal (NT-proBNP, NT-proANP). The main function of the active C-terminal natriuretic peptides is to counteract the renin-angiotensin-aldosterone system. They generally act to decrease blood volume and blood pressure through natriuresis, diuresis, vasodilation and direct inhibition of renin and aldosterone. They exert these actions mainly through interaction with the NPR-A receptor (Potter 2011). Clearance of the natriuretic peptides occurs through cleavage by membrane-bound neutral endopeptidases, internalization and lysosomal degradation via the NPR-C receptor, or through excretion in the urine or bile (Pro?ek and Ettinger, 2010). The half-life of ANP is shorter than BNP in humans as it has a higher affinity for the NPR-C receptor (Suga et al. 1992). The half-life of the N-terminal is longer than the active C-terminal, which only lasts a few minutes in circulation, as the N-terminal depends more on excretion by the liver and kidney (Potter 2011). In the dog, the half-life of C terminal BNP is shorter than in humans, and is more similar to ANP (Thomas and Woods 2003). The half-life of NT-proBNP has not been reported in dogs. Nevertheless, based on human data, NT-proBNP is assumed to be relatively more stable and therefore, to be a more attractive biomarker. Natriuretic peptide assaysC-terminal ANPHomology between feline, canine and human C-terminal ANP is high (Biondo et al. 2002; Hori et al. 2008a), and so previous veterinary studies measuring this biomarker have successfully used a human assay (Haggstrom et al. 2000; Hori et al. 2008b). However, given that this test is not readily available, there are a limited number of veterinary studies measuring C-terminal ANP, and results are sometimes conflicting, it is not recommended to routinely measure this biomarker. N-terminal proANPVeterinary studies measuring NT-proANP using a human assay have demonstrated its use in differentiating cardiac and respiratory disease, and in determining prognosis of mitral valve disease (Prosek et al. 2007; Connolly et al. 2008; Eriksson et al. 2014). However, it is not readily available to veterinary practitioners and so its routine use is not currently recommended. C-terminal BNPStudies measuring C-terminal BNP in dogs have used a canine specific radioimmunoassay. These studies have demonstrated a possible use for C-terminal BNP in differentiating cardiac from respiratory disease (DeFrancesco et al. 2007; Prosek et al. 2007), in predicting mortality in myxomatous mitral valve disease (MacDonald et al. 2003) and in detection of occult dilated cardiomyopathy (Oyama et al. 2007). The same canine assay used in cats was of limited use clinically (MacDonald et al. 2006). There is a commercially available assay for C-terminal BNP available in the USA (ANTECHTM Cardio-BNP canine), but it is not currently available in Europe. N-terminal BNP This is the most familiar, most widely used and most stable of the natriuretic peptide biomarkers. First generation NT-proBNP assays required shipment of samples frozen or in a tube containing a protease inhibitor in order to prevent degradation of the sample. However, more recently a second-generation assay (Canine and Feline Cardiopet? proBNP Assay IDEXX Laboratories Inc., Westbrook, Maine, USA) has been developed which allows shipment of EDTA plasma in a plain tube at room temperature, although shipping on ice is recommended if a delay of more than 48 hours is expected. Plain serum (without protease inhibitor or EDTA) is not suitable for shipment at room temperature (Hezzell et al. 2015; Mainville et al. 2015). This second-generation ELISA targets epitopes at a more stable region of the NT proBNP molecule than the first-generation assay and has been validated for use in both dogs (Cahill et al. 2015) and cats (Mainville et al. 2015). The canine second-generation assay has a higher upper detection limit of 10,000 pmol/l, compared to the previous limit of 3000 pmol/l with the first-generation assay. The feline assay has a range of detection of 24-1500pmol/l. A point-of-care SNAP test for cats is available (SNAP? Feline proBNP, IDEXX Laboratories Inc., Westbrook, Maine, USA). This ELISA SNAP test uses serum or EDTA plasma and provides a positive or negative result within 10 minutes. The test uses the same antibodies as the second generation quantitative ELISA and becomes positive somewhere between 100-200pmol/l (SNAP? Feline proBNP data sheet, Hezzell et al. 2016). There are several limitations of the NT-proBNP assay that should be taken into account when interpreting results. Firstly, there is large biologic variability in NT-proBNP between individuals, as well as moderate variability within the individual when repeated measures are taken over days to weeks (Kellihan et al. 2009; Harris et al. 2017; Winter et al. 2017). This suggests that subject-based reference intervals and “monitoring the trend” may be more relevant than population based intervals. A change of 70.8% is required in a healthy dog to be considered a significant change, and 58.2% in a dog with myxomatous mitral valve disease (Winter et al. 2017). A change of 39.8% between days and 60.5% between weekly measurements is required to be considered significant in the cat (Harris et al. 2017). There also appears to be considerable interbreed variation in NT-proBNP, with healthy Labradors and Newfoundlands having the highest concentrations, and Dachshunds having the lowest (Sj?strand et al. 2014). Plasma NT-proBNP in healthy Labradors is frequently above current laboratory reference ranges (Borgeat et al. 2017) but breed specific reference ranges are yet to be published. Secondly, NT-proBNP can be affected by comorbid conditions. Renal dysfunction can result in a significant increase in NT-proBNP in dogs (Raffan et al. 2009, Schmidt et al. 2009) and cats (Lalor et al. 2009). It was previously thought that this was due to passive accumulation secondary to decreased renal clearance. However, this hypothesis has recently been challenged by a paper in dogs showing no correlation between glomerular filtration rate and NT-proBNP (Pelander et al. 2017). The increase in NT-proBNP seen with renal dysfunction may instead be due to increased production. Additionally, Bijman et al 2017 found an increase in NT-proBNP in hypertensive CKD cats but not in those with CKD but no hypertension, suggesting that hypertension may be the cauchronic kidney disease than non-hypertensive cats with chronic kidney diseaseHypertension and uncontrolled hyperthyroidism can be associated with an increase in NT-proBNP in cats (Lalor et al. 2009, Sangster et al. 2014). False positive results can also occur due to the presence of pulmonary hypertension secondary to primary respiratory disease having an effect on the heart (Oyama et al. 2009). Uses of NT-proBNP in clinical practiceDifferentiation of cardiac from non-cardiac causes of respiratory signs Dogs: There are several studies demonstrating the utility of NT-proBNP measurement in diagnosing congestive heart failure (CHF) in dogs presenting with respiratory distress. Studies using the first-generation assay identified various cut-off values of >1158 pmol/l (Oyama et al. 2009), >1400pmol/l (Fine et al. 2008) and >1725pmol/l (Oyama et al. 2008) as suggestive of CHF. One study by Boswood et al. (2008) identified a cut-off value of >210pmol/l as being relatively sensitive and specific for CHF. It is unknown why this value is so much lower than other studies. Fox et al. (2015) have more recently performed a similar study using the second-generation NT-proBNP ELISA. They identified an optimal cut-off of >2447pmol/l as 81.1% sensitive and 73.1% specific to discriminate between cardiac and non-cardiac causes of respiratory distress. A lower cut-off would increase the sensitivity but at the expense of specificity, and a higher cut-off vice versa. The current recommendation from IDEXX is that a value of >1800pmol/l is highly suggestive of CHF in a patient presenting with appropriate signs (Table 1). Unfortunately, the practical use of NT-proBNP measurement to differentiate congestive heart failure from other causes of respiratory distress is limited in dogs, as the sample must be sent to a laboratory and so results are not immediate. The suspected diagnosis must therefore be made through other methods such as physical examination, thoracic radiography and echocardiography. A value >1800pmol/l may support your diagnosis, but usually results will not be available until treatment has started. A value <900pmol/l makes CHF very unlikely. Cats: The accuracy of NT-proBNP for differentiating cardiac from respiratory causes of dyspnoea in cats appears to be even higher than for dogs. Initial studies using the first-generation ELISA all identified similar cut-offs of > 220pmol/l (Connolly et al. 2009), >277pmol/l (Wess et al. 2008), >265pmol/l (Fox et al. 2009) and >214.3pmol/l (Humm et al. 2013) for diagnosing CHF. A more recent study by Hezzell et al. (2016) using the second-generation ELISA identified a cut-off of >199pmol/l to have a sensitivity of 95.2% and specificity of 82.4% for diagnosing CHF in cats with pleural effusion. IDEXX suggests a cut-off of >270pmol/l as suggestive of CHF in cats with appropriate clinical signs and <100pmol/l as very unlikely in CHF (Table 1). The point-of-care SNAP test also has good diagnostic accuracy for identifying CHF, with a positive test having a sensitivity of 95.2% and specificity of 87.5% in cats with pleural effusion (Hezzell et al. 2016). The point-of-care test is likely the most practical in this situation, as results are available immediately. The point-of-care test has a high negative predictive value and so is recommended mainly as a rule-out test, meaning that if the result is negative then congestive heart failure is most likely ruled out but if it is positive then congestive heart failure could be the cause of dyspnoea, but another cause is also possible. Two studies have measured NT-proBNP in pleural fluid. Using the first-generation assay, a cut off of >322.3pmol/L had 100% sensitivity and 94.4% specificity for identifying a cardiogenic cause of pleural effusion (Humm et al. 2013). The second study, using the second-generation assay, identified a cut-off of >240pmol/l in pleural fluid to have a sensitivity of 100% but poorer specificity of 76.5%, suggesting that false positive results are possible (Hezzell et al. 2016). A positive result on the point-of-care SNAP test using pleural fluid had good sensitivity for detection of CHF but specificity was poor at 64.7%. Although no recommendations have been made by the manufacturer for measurement of NT-proBNP in pleural fluid, point-of-care SNAP testing may be a practical and quick way to rule-out CHF as a cause of pleural effusion in patients for which blood sampling is too distressing, and thoracic radiography and/or echocardiography is not available or possible. Detecting occult heart diseaseDog: NT-proBNP is relatively accurate for predicting echocardiographic changes associated with occult dilated cardiomyopathy (DCM) in Doberman Pinschers, using a cut-off of 400pmol/l (Wess et al. 2011) or 457pmol/l (Singletary et al. 2012). However, its sensitivity is much poorer for detecting occult DCM in dogs with solely arrhythmogenic changes. A combination of NT-proBNP and 24 hour Holter monitor provided improved accuracy. IDEXX recommends a cut-off of >735pmol/l for detecting occult dilated cardiomyopathy in Doberman Pinschers based on a 2013 abstract (Gordon et al. 2013) (Table 1), although a 2015 abstract by the same group (Gordon et al 2015) suggested a cut-off of 548pmol/l. Measurement of NT-proBNP is not recommended to replace echocardiography and 24 hour Holter monitoring, which is considered the gold standard for detection of occult DCM. The European Society of Veterinary Cardiology screening guidelines for dilated cardiomyopathy in Doberman Pinschers (2017) suggest that it may be reasonable to screen Doberman Pinschers over the age of 3-4 years with NT-proBNP if there are financial concerns which prevent gold standard screening. However, a positive result should be followed up with confirmatory tests before making a diagnosis and initiating treatment. Wess et al, 2011 found that NT-proBNP was increased in dogs 1.5 years before development of echocardiographic or arrhythmogenic signs of DCM, but further validation of these results would be required before recommendations can be made. Cat: Cut-offs of 100pmol/l in two studies using the second-generation NT-proBNP assay resulted in relatively good sensitivity and specificity (Machen et al. 2014; Harris et al. 2017) for detecting occult heart disease in cats with history or physical exam findings suggestive of cardiac disease. Two studies looking at the POC test were slightly conflicting in their results, Machen et al, 2014 finding more false positive results (positive predictive value (PPV) of 62% and negative predictive value (NPV) of 93.8%) and Harris et al, 2017 finding more false negative results (PPV 100%, NPV 87.1%). This may be in part because the prevalence of disease was lower in the first study than the second (25% vs. 50%). In a general practice population, it is likely the prevalence would be even lower, which would further decrease the PPV but increase the NPV, therefore making false positives more likely but false negatives less likely. The quantitative and POC assays appear to be insensitive for mild disease, but better for moderate or severe disease (Hsu, Kittleson and Paling, 2009; Machen et al, 2014). As the assays have only been investigated in cats with a suggestion of heart disease, indiscriminate testing of apparently healthy cats, particularly younger cats, is not recommended as this will increase the risk of a false positive. Between 16-44% of cats have murmurs (Cote et al. 2004; Paige et al. 2009; Wagner et al. 2010), and between 16-77% of these have occult heart disease (Paige et al. 2009; Dirven et al. 2010; Wagner et al. 2010; Nakamura et al. 2011) the rest being physiologic or innocent murmurs. Current recommendations are that adult cats with ≥ grade III/VI murmurs, gallop rhythms or arrhythmias should undergo echocardiography to identify occult heart disease (Cote et al. 2015). NT-proBNP may be used to aid in compliance in these cats. In other words, NT-proBNP >100pmol/l or a positive NT-proBNP POC assay identifies the cats at most risk of occult heart disease and so may encourage owners to proceed with echocardiography. However, NT-proBNP should not be used alone to rule in or out cardiac disease in these cats. In cats with ≤ grade II murmur, echocardiography is less strongly recommended, although is still the most sensitive way to detect occult heart disease and even cats in heart failure may not have a murmur. NT-proBNP can be measured in these cats and if >100pmol/l then echocardiography more strongly recommended. If NT-proBNP is <50pmol/l then significant heart disease is less likely, but keep in mind that heart disease can develop over time so annual re-assessment of the patient is advised (Cote et al. 2015). Use of NT-proBNP in determining prognosisDogs: NT-proBNP is correlated with the severity of MMVD (Oyama et al. 2008, Chetboul et al. 2009). A cut-off value of >1500pmol/l has been determined as an independent risk-factor for the development of congestive heart failure within 3-6 months (Reynolds et al. 2012) in dogs with asymptomatic MMVD and as predictive of mortality within 6 months in dogs with MMVD and CHF (Serres et al. 2009). In two other studies, lower values of >466pmol/l or >740pmol/l have been predictive of progression of disease or mortality in dogs with MMVD (Chetboul et al. 2009; Moonarmart et al. 2010). Dogs that continue to have elevated NT-proBNP >965pmol/l 7-30 days after starting treatment for CHF have a shorter survival time (Wolf et al. 2012). NT-proBNP >900pmol/l was predictive of all-cause mortality in Doberman Pinschers with occult dilated cardiomyopathy (Singletary et al. 2012). A value <2,966pmol/l has a sensitivity of 71% and specificity of 88% for detecting resolution of CHF in dogs with MMVD, but sleeping respiratory rate remains more sensitive and specific for this purpose (Schober 2011). NT-proBNP >900pmol/l was predictive of all-cause mortality in Doberman Pinschers with occult dilated cardiomyopathy (Singletary et al. 2012). Unfortunately, the above studies all used the first-generation assay and so the cut-offs mentioned likely do not apply when using the current, second-generation assay.Cats: NT-proBNP also appears to be correlated with severity of cardiomyopathy in cats (Fox et al. 2011; Machen et al. 2014). Cats with a larger reduction in NT-proBNP from admission to discharge have a longer survival than those with a smaller reduction, but further research is required to identify exact cut-offs and percent decreases (Pierce et al. 2017). Other factors such as left atrial size and the presence of CHF are likely more reliable prognostic indicators in cats. Cardiac troponinsPhysiologyThe cardiac troponins are proteins that mediate the interaction of actin with myosin. There are three forms of cardiac troponin; cardiac troponin C, I and T (Figure 1). Cardiac troponin I (cTnI) inhibits hydrolysis of ATP required for actin and myosin interaction (Langhorn and Willesen 2016). When cardiac troponin C (cTnC) binds Ca2+, it loosens the bond between cTnI and actin, removing the inhibitory effects of cTnI and allowing tropomyosin to be removed from the myosin binding site of actin. Cardiac troponin T (cTnT) binds tropomyosin and the troponin complex to actin (Gomes et al. 2002; Katz 2011). When myocardial cell death or damage occurs, troponin proteins are released quickly from a cytosolic pool and more slowly from the bound complex (Langhorn and Wellesen 2016). cTnI and cTnT have specific cardiac isoforms and so are very specific for myocardial damage. Cardiac and skeletal troponin C are structurally the same and so it is not a clinically useful cardiac biomarker. cTnI is more sensitive for myocardial damage than cTnT as it is more easily released, possibly because cTnT is more tightly bound (Schober et al. 1999). Therefore, cTnI is the more popular cardiac biomarker. An increase in cTnI in the blood can be detected 2-7hrs after damage occurs, and peaks within 18-48 hours. The blood levels then fall over the following days to weeks (Pro?ek and Ettinger 2010; Langhorn and Willesen 2016), depending on if there is ongoing myocardial damage. The method of elimination has not been confirmed, although proteolysis, reticuloendothelial degradation and renal excretion likely all play a role (Langhorn and Willesen 2016). Cardiac troponin assays: There are currently at least 15 different assays for cardiac troponin I on the market, all with antibodies directed towards different epitopes, meaning that comparisons cannot be made between measurements from different assays. The majority are human assays, but homology between human, canine and feline cTnI is very high. Only two have been validated in dogs and one in cats (Oyama and Salter 2005, Langhorn et al. 2013). The more recently developed assays are “high-sensitivity” assays and so can detect cTnI at increasingly lower levels in the blood. There is a point-of-care assay available (i-STAT? Cardiac Troponin I (cTnI), Abbott Point of Care, Princeton, NJ) meaning that results can be available to the clinician within 10 minutes (Figure 2). There is a single assay available for cTnT, which has not been validated for dogs and cats. However, it has been used successfully in several studies in dogs (DeFrancesco et al. 2002; Tarducci et al 2004; Shaw et al. 2004) and one study in cats (Langhorn et al. 2014). Measurement of cTnI has several limitations. Renal disease can result in an increase in circulating cTnI, as at least some of the degradation products of cTnI are renally excreted (Porciello et al. 2008; Sharkey et al. 2009). Other extra-cardiac diseases can also result in an elevation in cTnI by causing secondary myocardial damage, through release of inflammatory cytokines, oxidative damage, hypoxia and other mechanisms. Therefore, elevated cTnI is seen with systemic disease such as anaemia (Lalor et al. 2014), immune-mediated haemolytic anaemia (Cartwright et al. 2015), gastric dilation and volvulus (Schober et al. 2002), systemic inflammatory response syndrome (Langhorn et al. 2013; Langhorn et al. 2014, Hamacher et al. 2015), hyperthyroidism (Connolly et al. 2005) and systemic and pulmonary hypertension (Bijmans et al. 2017; Guglielmini et al. 2010), among others. cTnI also increases with age (Oyama et al. 2004; Ljungvall et al. 2010) and is higher in certain breeds such as Greyhounds (LaVecchio et al. 2009) and Boxers (Baumwart et al. 2007). Mishandling of the sample can also result in false cTnI results. It has been reported that serum samples are not stable at room temperature, 4?C or -20?C (O’Brien et al. 2006). However, some laboratories still allow shipment of refrigerated samples, so it is important to check the guidelines of the individual laboratory before shipping. Point-of-care tests should be run immediately after collection for the most accurate results. Lipaemia or haemolysis of the sample can also result in false elevation (Langhorn and Wellesen 2016). Uses of cTnI in clinical practiceDifferentiation of cardiac from non-cardiac causes of respiratory signs Dogs: cTnI does not appear to be useful in differentiating cardiac from primary respiratory causes of dyspnoea (Pro?ek et al. 2007; Payne et al. 2011). Although circulating cTnI levels were higher in cardiogenic cases of respiratory distress in one study using the point-of-care iSTAT analyser (Payne et al. 2011), there was significant overlap meaning that the specificity of the test was very poor. This is likely due to increases in cTnI due to hypoxic damage to the myocardium. Cats: cTnI may be slightly more useful in cats to differentiate cardiac from non-cardiac causes of dyspnoea, although significant overlap still does occur (Connolly et al. 2009). The most recent study using the point-of-care iSTAT analyser identified a cut-off of 0.24ng/ml to have 100% sensitivity and a cut-off of 0.66ng/ml to have 100% specificity for cardiogenic dyspnea (Wells et al. 2014). The range of values between these cut-offs represents a grey-area. These results are similar to a previous study by Herndon et al (2008) who found a lower cut-off of 0.19ng/ml and an upper cut-off of 1.42ng/ml to have 100% sensitivity and specificity respectively. Cats with HCM and congestive heart failure have higher cTnI than cats with HCM but without CHF (Herndon et al. 2002). As with NT-proBNP, this test should only be used as an aid in diagnosis and other confirmatory tests such as thoracic radiography and echocardiography should be performed, particularly because concurrent renal disease is a common comorbidity in cats with CHF and can result in elevation of cTnI. Detecting occult heart diseaseDogs: An earlier study by Oyama et al. (2007) did not find cTnI useful in detecting occult DCM. However, a 2010 study by Wess et al. found that a cut-off of >0.22ng/mL had a sensitivity of 79.5% and specificity of 84.4% for detecting all forms of cardiomyopathy in Dobermans. The sensitivity was slightly better for echocardiographic changes (86.6%), and slightly worse for arrhythmogenic changes (70.5%). Similar to NT-proBNP, The European Society of Veterinary Cardiology screening guidelines for dilated cardiomyopathy in Doberman Pinschers (2017) suggest that cTnI may be suitable as a screening tool when the gold standard is unavailable, but a positive result should be followed up with echocardiography and Holter monitoring before a diagnosis is made. Equally, a negative result cannot rule-out the presence of occult DCM. Just as with NT-proBNP, cTnI was shown by Wess et al (2010) to be elevated 1.5 years before the development of echocardiographic or arrhythmogenic signs of DCM but further investigation is necessary before additional recommendations can be made. Cats: Two studies have shown higher levels of cTnI in cats with moderate to severe HCM compared to normal cats (Herndon et al. 2002; Connolly et al. 2003). However, the HCM groups in these studies contained cats with both occult HCM and CHF. Connolly et al. (2003) described a cut-off of 0.2ng/ml to have a sensitivity of 87% and specificity of 84% for the presence of HCM, which was the lower limit of detection of the assay used at the time. Further studies are required before recommendations can be made for the use of cTnI in detection of occult cardiomyopathy in cats. Use of cTnI in determining prognosisDogs: In general, cTnI levels are associated with the severity of cardiac disease in dogs (Oyama et al. 2004; Spratt et al. 2005; Ljungvall et al. 2010; Polizopoulou et al 2014). Dogs with cardiomyopathy and cTnI >0.2ng/ml had a shorter survival time than those with cTnI <0.2ng/ml (Oyama et al. 2004). Similarly, Kluser et al (2016) found that cTnI >0.34ng/ml predicted an increased risk of sudden death in Doberman Pinschers with dilated cardiomyopathy but in this study, other factors such as heart size, NT-proBNP and the presence of ventricular tachycardia were more important predictors. Linklater et al. (2007) suggested that in dogs with MMVD presenting with CHF, an undetectable cTnI value using an assay with a lower detection limit of 0.1ng/ml might have a longer survival time than those with detectable cTnI. Hezzell et al. (2012) used a higher sensitivity assay and identified a value of >0.025ng/ml to be associated with a 1.9 times increased risk of death in dogs with MMVD. A more rapid rate of increase in cTnI was also associated with an increased risk of mortality in this study, although the sudden increase in cTnI occurred late in life. Fonfara et al. (2010) looked at dogs with cardiac disease of any cause and found that dogs with cTnI <0.15ng/ml had a better survival than those with presenting values between 0.151ng/ml and 1ng/ml. Dogs with cTnI >1ng/ml had an even worse prognosis. In the group of dogs with cTnI >1ng/ml at presentation, persistent elevation of cTnI at a 2 month recheck was associated with a shorter survival time. Cats: Two 2014 studies have looked at the value of cardiac troponins as prognostic indicators in cats with HCM. Langhorn et al. (2014) used only purebred cats and identified a cTnI value of > 0.14ng/ml at admission to have a sensitivity of 80% but a poor specificity of 61.5% for cardiac death during the follow-up period. cTnT of >13ng/mL at admission had a lower sensitivity (60%) but higher specificity (84.6%), and the final cTnT value before death also had prognostic potential, overall making cTnT a better prognostic indicator than cTnI. Borgeat et al. (2014) found that cats with HCM and a cTnI value of >0.7ng/ml had a significantly shorter survival time, although significance was lost if the regional left ventricular wall hypokinesis was detected on echocardiography. Overall, the low sensitivities and specificities of cTnI and cTnT make them unsuitable for use as sole prognostic indicators and other prognostic factors such as left atrial size, left ventricular thickness and systolic function and the presence of CHF should be taken into account. They are probably most useful when echocardiography is unavailable. Other uses for cTnIMyocarditis: Some of the most dramatic increases in cTnI are seen in dogs and cats with myocarditis, with values often hundreds of times greater than the upper reference value. Values are generally expected to be higher than with other cardiac diseases, due to the acute, diffuse myocardial cell death and damage that occurs. However, myocarditis is not often proven in veterinary medicine as endomyocardial biopsy is rarely undertaken and cTnI levels, along with the clinical picture, are instead used to make a presumptive diagnosis. Pericardial effusion: cTnI is elevated in dogs with pericardial effusion, and is higher in dogs with haemangiosarcoma than idiopathic pericardial effusion (Shaw et al. 2004). A cTnI value >0.25ng/ml suggests that pericardial effusion is neoplastic in origin, with high sensitivity (81%) and specificity (100%) (Chun et al. 2010). Collapse: cTnI values are higher in dogs with cardiogenic causes of collapse than neurological or vaso-vagal causes. However, its use as a diagnostic test in this sense is limited as there is significant overlap between groups (Dutton et al. 2017). Systemic inflammatory response syndrome (SIRS): cTnI is prognostic for short-term survival in patients with SIRS, with a value <0.24ng/ml being an excellent predictor of short-term survival. However, values >0.24ng/ml are not necessarily suggestive of death (Langhorn et al. 2013). cTnI and cTnT have poor sensitivity and specificity to determine long-term (1 year) outcome (Langhorn et al. 2014).ConclusionsCardiac biomarkers have proven to be a useful addition to clinical practice for diagnosis and prognostication in cardiac and some non-cardiac diseases. However, they must be used and interpreted appropriately to have the most benefit. Indiscriminate measurement will result in an increased number of false positive results so testing is only recommended if there is already a suspicion of disease based on signalment, history, physical examination and/or other diagnostic findings and results should be interpreted in light of these other findings. It is important to remember that biomarkers are not diagnostic for any one disease, and positive results should always be followed up with appropriate confirmatory diagnostic tests.Key WordsBiochemical markers; troponin; natriuretic peptides; heart; canine; felineKey-pointsThe natriuretic peptides are released in response to myocardial stretch. The NT-proBNP assay is the most studied and widely available of the natriuretic peptide family.The cardiac troponins are released in response to myocardial cell damage or death. Cardiac troponin I is the most studied and widely available assay. Measurement of NT-proBNP in dogs and particularly in cats can aid in the differentiation of respiratory signs due to cardiac versus non-cardiac disease. cTnI is not as useful for this purpose. NT-proBNP and cTnI measurement may be useful in screening Doberman Pinschers for DCM when the gold standard (echocardiography and Holter monitoring) is not available. Their sensitivity is lower in dogs with solely arrhythmogenic changes than those with structural changes. NT-proBNP is relatively sensitive for the detection of moderate to severe occult heart disease in cats when there is a clinical suspicion of heart disease. cTnI is less well studied.NT-proBNP and cTnI levels are generally associated with severity of disease and may be helpful in determining prognosis, but other clinical and echocardiographic findings are likely to be more useful for this purpose. Indiscriminate testing is not recommended as this increases the risk of false positive results. All positive results must be followed up with confirmatory diagnostic tests before a definitive diagnosis can be made. References Baumwart RD, Orvalho J, Meurs KM. Evaluation of serum cardiac troponin I concentration in boxers with arrhythmogenic right ventricular cardiomyopathy. Am J Vet Res 2007;68(5):524–528.Bijsmans ES, Jepson RE, Wheeler C, Syme HM, Elliott J. Plasma N-Terminal Probrain Natriuretic Peptide, Vascular Endothelial Growth Factor, and Cardiac Troponin I as Novel Biomarkers of Hypertensive Disease and Target Organ Damage in Cats. J Vet Intern Med 2017;31(3):650-660. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.Biondo AW, Ehrhart EJ, Sisson DD, Bulmer BJ, De Morais HS, Solter PF. Immunohistochemistry of atrial and brain natriuretic peptides in control cats and cats with hypertrophic cardiomyopathy. Vet Pathol. 2003;40(5):501-506. Biondo AW, Liu ZL, Wiedmeyer CE, de Morais HS, Sisson DD, Solter PF. Genomic sequence and cardiac expression of atrial natriuretic peptide in cats. Am J Vet Res. 2002;63(2):236–240.Borgeat K, Sherwood K, Payne JR, Luis Fuentes V, Connolly DJ. Plasma cardiac troponin I concentration and cardiac death in cats with hypertrophic cardiomyopathy. J Vet Intern Med 2014;28(6):1731–1737.Borgeat K, Gomart S, Harrison M, Colyer A, Glen FJ, Payne JR, Hezzell MJ, Allaway D. Biological variability of N-terminal pro-B-type natriuretic peptide in fifty-three healthy labrador retrievers over an 8 month period [abstract]. In: Proceedings of the 27th ECVIM-CA Congress; 2017 Sept 14-16; St. Julians, Malta.Boswood A, Dukes-McEwan J, Loureiro J, James RA, Martin M, Stafford-Johnson M, Smith P, Little C, Attree S. The diagnostic accuracy of di?erent natriuretic peptides in the investigation of canine cardiac disease. J Small Anim Pract. 2008;49(1):26–32.Cahill RJ, Pigeon K, Strong-Townsend MI, Drexel JP, Clark GH, Buch JS. Analytical validation of a second-generation immunoassay for the quantification of N-terminal pro–B-type natriuretic peptide in canine blood J Vet Diagn Invest. 2015;27(1):61-67.Cartwright JA, Gow DJ, Gow AG, Handel I, Reed N, Brown AJ, Cash R, Foote A, Mackenzie D, Bell R, Mellanby RJ. Serum cardiac troponin I concentrations decrease following treatment of primary immune-mediated haemolytic anaemia. J Small Anim Pract 2015;56(8):516-20. Chetboul V, Serres F, Tissier R, Lefebvre HP, Sampedrano CC, Gouni V, Poujol L, Hawa G, Pouchelon J. Association of plasma N-terminal pro-B-type natriuretic peptide concentration with mitral regurgitation severity and outcome in dogs with asymptomatic degenerative mitral valve disease. J Vet Intern Med. 2009;23(5):984-94. Chun R, Kellihan HB, Henik RA, Stepien RL. Comparison of plasma cardiac troponin I concentrations among dogs with cardiac hemangiosarcoma, noncardiac hemangiosarcoma, other neoplasms, and pericardial e?usion of non-hemangiosarcoma origin. J Am Vet Med Assoc 2010;237(7):806-11.Connolly D, Cannata J, Boswood A, et al. Cardiac troponin I in Cats with hypertrophic cardiomyopathy. J Feline Med Surg 2003;5:209–216Connolly DJ, Brodbelt DC, Copeland H, Collins S, Fuentes VL. Assessment of the diagnostic accuracy of circulating cardiac troponin I concentration to distinguish between cats with cardiac and non-cardiac causes of respiratory distress. J Vet Cardiol 2009;11(2):71-8.Connolly DJ, Guitian J, Boswood A, Neiger R. Serum troponin I levels in hyperthyroid cats before and after treatment with radioactive iodine. J Feline Med Surg 2005;7:289-300.Connolly DJ, Magalhaes RJS, Syme HM, Boswood A, Fuentes VL, Chu L, Metcalf M. Circulating natriuretic peptides in cats with heart disease. J Vet Intern Med. 2008;22:96–105.Connolly DJ, Soares Magalhaes RJ, Fuentes VL, Boswood A, Cole G, Boag A, Syme HM. Assessment of the diagnostic accuracy of circulating natriuretic peptide concentrations to distinguish between cats with cardiac and non-cardiac causes of respiratory distress. J Vet Cardiol. 2009;11(S1):S41–S50.C?té E, Edwards NJ, Ettinger SJ, Fuentes VL, MacDonald KA, Scansen BA, Sisson DD, Abbott JA. Management of incidentally detected heart murmurs in dogs and cats. J Vet Cardiol. 2015;17: 245-261.C?té E, Manning AM, Emerson D, Laste NJ, Malakoff RL, Harpster NK. Assessment of the prevalence of heart murmurs in overtly healthy cats. J Am Vet Med Assoc. 2004;225:384-388. DeFrancesco TC, Atkins CE, Keene BW, Coats JR, Hauck ML. Prospective clinical evaluation of serum cardiac troponin T in dogs admitted to a veterinary teaching hospital. J Vet Intern Med 2002;16:553–557.DeFrancesco TC, Rush JE, Rozanski EA, Hansen BD, Keene BW, Moore DT, Atkins CE. Prospective clinical evaluation of an ELISA B-type natriuretic peptide assay in the diagnosis of congestive heart failure in dogs presenting with cough or dyspnea. J Vet Intern Med. 2007;21(2):243-50.Dirven MJ, Cornelissen JM, Barendse MA, van Mook MC, Sterenborg JA. Cause of heart murmurs in 57 apparently healthy cats. Tijdschr Diergeneeskd. 2010;135:840-847. Dutton E, Dukes-McEwan J and Cripps PJ. Serum cardiac troponin I in canine syncope and seizures. J Vet Cardiol. 2017;19:1-13. Eriksson AS, Haggstrom J, Pedersen HD, Hansson K, J?rvinen AK, Haukka J, Kvart C. Increased NT–proANP predicts risk of congestive heart failure in Cavalier King Charles spaniels with mitral regurgitation caused by myxomatous valve disease. J Vet Cardiol. 2014;16(3):141-54.Erne P, Raine AE, Burgisser E, Gradel E, Burkart F, Buhler FR. Paradoxical inhibition of atrial natriuretic peptide release duing pacing-induced hypotension. Clin Sci. 1987;73(5):459–462.Fine DM, DeClue AE, Reinero CR. Evaluation of circulating amino terminal-pro-B-type natriuretic peptide concentration in dogs with respiratory distress attributable to congestive heart failure or primary pulmonary disease. J Am Vet Med Assoc. 2008;232:1674–167.Fonfara S, Loureiro J, Swift S, et al. Cardiac troponin I as a marker for severity and prognosis of cardiac disease in dogs. Vet J 2010;184:334–339.Fox PR, Oyama MA, Hezzell MJ, Rush JE, Nguyenba TP, DeFrancesco TC, Lehmkuhl LB, Kellihan HB, Bulmer B, Gordon SG, Cunningham SM, MacGregor J, Stepien RL, Lefbom B, Adin D, Lamb K. Relationship of Plasma N-terminal Pro-brain Natriuretic Peptide Concentrations to Heart Failure Classi?cation and Cause of Respiratory Distress in Dogs Using a 2nd Generation ELISA Assay. J Vet Intern Med. 2015;29:171–179.Fox PR, Oyama MA, Reynolds C, Rush JE, DeFrancesco TC, Keene BW, Atkins CE, Macdonald KA, Schober KE, Bonagura JD, Stepien RL, Kellihan HB, Nguyenba TP, Lehmkuhl LB, Lefbom BK, Moise NS, Hogan DF. Utility of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) to distinguish between congestive heart failure and non-cardiac causes of acute dyspnea in cats. J Vet Cardiol. 2009;11(S1):S51–S61.Fox PR, Rush JE, Reynolds CA, Defrancesco TC, Keene BW, Atkins CE, Gordon SG, Schober KE, Bonagura JD, Stepien RL, Kellihan HB, Macdonald KA, Lehmkuhl LB, Nguyenba TP, Sydney Moise N, Lefbom BK, Hogan DF, Oyama MA. Multicenter evaluation of plasma N-terminal probrain natriuretic peptide (NT-pro BNP) as a biochemical screening test for asymptomatic (occult) cardiomyopathy in cats. J Vet Intern Med. 2011;25(5):1010-6.Fu Z, Wong EF, Yeug-Lai-Wah JA, Wong NL. Effect of pacing on epinephrine- stimulated atrial natriuretic factor release. Cardiology 1992;81(2–3):85–88. Goetze JP, Gore A, Moller CH, Steinbrüchel DA, Rehfeld JF, Nielsen LB. Acute myocardial hypoxia increases BNP gene expression. FASEB J. 2004;18:1928-1930.Gomes AV, Potter JD, Szczesna-Cordary D. The Role of Troponins in Muscle Contraction. IUBMB Life. 2002;54: 323–333.Gordon S, Braz-Ruivo L, Drourr L, Estrada A; Meurs K, Morris N, O'Grady M, Oyama M. Prospective evaluation of NT-proBNP, high sensitivity Troponin I and PDK4 for the detection of occult DCM in 225 Doberman Pinchers. Presented at: 2013 ACVIM Forum; June 2013;Seattle, WA.Gordon S, Estrada AH, Braz-Ruivo L, Drourr L, Morris N, O'Grady R, Boggess M. Evaluation of NT-proBNP, High Sensitivity Troponin I and PDK4 for the Detection of Occult DCM: A Prospective Study in 449 Doberman Pinschers. Presented at: 25th ECVIM-CA Congress; September 2015; Lisbon, Portugal. Guglielmini C, Civitella C, Diana A, Di Tommaso M, Cipone M, Luciani A. Serum cardiac troponin I concentration in dogs with precapillary and postcapillary pulmonary hypertension. J Vet Intern Med 2010;24:145– 152.Haggstrom J, Hansson K, Kvart C, Pedersen HD, Vuolteenaho O, Olsson K. Relationship between different natriuretic peptides and severity of naturally acquired mitral regurgitation in dogs with chronic myxomatous valve disease. JVet Cardiol. 2000;2(1):7–16.Hamacher L, Doerfelt R, Mueller M, Wess G. Serum cardiac troponin I concentrations in dogs with systemic in?ammatory response syndrome. J Vet Intern Med 2015;29:164–170.Harris AN, Beatty SS, Estrada AH, Winter B, Bohannon M, Sosa I, Hanscom J, Mainville CA, Gallagher AE. Investigation of an N-Terminal Prohormone of Brain Natriuretic Peptide Point-of-Care ELISA in Clinically Normal Cats and Cats With Cardiac Disease. J Vet Intern Med. 2017;31(4):994-999.Harris AN, Estrada AH, Gallagher AE, Winter B, Lamb KE, Bohannon M, Hanscom J, Mainville CA. Biologic variability of N-terminal pro-brain natriuretic peptide in adult healthy cats J Feline Med Surg. 2017;19(2):216 –22.Herndon W, Kittleson M, Sanderson K, Drobatz KJ, Clifford CA, Gelzer A, Summerfield NJ, Linde A, Sleeper MM. Cardiac troponin I in feline hypertrophic cardiomyopathy. J Vet Intern Med 2002;16:558–564.Herndon WE, Rishniw M, Schrope D, Sammarco CD, Boddy KN, Sleeper MM. Assessment of plasma cardiac troponin I concentration as a means to differentiate cardiac and noncardiac causes of dyspnea in cats. J Am Vet Med Assoc 2008;233(8):1261-4.Hezzell MJ, Boswood A, Chang Y, Moonarmart W, Souttar K, Elliott J. The combined prognostic potential of serum high-sensitivity cardiac troponin I and N-terminal pro-B-type natriuretic peptide concentrations in dogs with degenerative mitral valve disease. J Vet Intern Med 2012;26:302–311.Hezzell MJ, Boswood A, L?tter N, Elliott J. The effects of storage conditions on measurements of canine N-terminal pro-B-type natriuretic peptide. J Vet Cardiol. 2015;17(1):34-41.Hezzell MJ, Rush JE, Humm K, Rozanski EA, Sargent J, Connolly DJ, Boswood A, and Oyama MA. Di?erentiation of Cardiac from Noncardiac Pleural E?usions in Cats using Second-Generation Quantitative and Point-of-Care NT-proBNP Measurement. J Vet Intern Med. 2016;30:536–542.aHori Y, Tsubaki M, Katou A, Ono Y, Yonezawa T, Li X, Higuchi SI. Evaluation of NT-pro BNP and CT- ANP as markers of concentric hypertrophy in dogs with a model of compensated aortic stenosis. J Vet Intern Med. 2008;22:1118–1123.bHori Y, Yamano S, Iwanaga K, Kano T, Tanabe M, Uechi M, Kanai K, Nakao R, Hoshi F, Higuchi S. Evaluation of plasma C-terminal atrial natriuretic peptide in healthy cats and cats with heart disease. J Vet Intern Med. 2008;22:135–139.Hsu A, Kittleson MD, Paling A. Investigation into the use of plasma NT-proBNP concentration to screen for feline hypertrophic cardiomyopathy. J Vet Cardiol. 2009;11(S1):S63-S70.Humm K, Hezzell M, Sargent J, Connolly DJ, Boswood A. Di?erentiating between feline pleural e?usions of cardiac and non-cardiac origin using pleural ?uid NT-proBNP concentrations. J Small Anim Pract 2013;54:656–661.Katz AM. 2011. The Contractile Proteins. In: Katz AM. Physiology of the heart, 5th Edition. Lippincott, Williams and Wilkins. Philidelphia (PA). p. 88-106. Kellihan HB, Oyama MA, Reynolds CA, Stepien RL. Weekly variability of plasma and serum NT-proBNP measurements in normal dogs. J Vet Cardiol. 2009;11(S1):S93–S97.Kluser L, Holler PJ, Simak J, Tater G, Smets P, Rugamer D, Kuchenhoff H, Wess G. Predictors of sudden cardiac death in Doberman Pinschers with dilated cardiomyopathy. J Vet Intern Med 2016;30:722-32.Lalor SM, Connolly DJ, Elliot J, Syme HM. Plasma concentrations of natriuretic peptides in normal cats and normotensive and hypertensive cats with chronic kidney disease. J Vet Cardiol 2009;11:S71–S79.Lalor SM, Gunn-Moore DA, Cash R, Foot A, Reed N, Mellanby RJ. Serum cardiac troponin I concentrations in cats with anaemia - a preliminary, single-centre observational study. J Small Anim Pract 2014;55:320–322.Langhorn R, Oyama MA, King LG, Machen MC, Trafny DJ, Thawley V, Willesen JL, Tarnow I, Kjelgaard‐Hansen M. Prognostic importance of myocardial injury in critically ill dogs with systemic in?ammation. J Vet Intern Med 2013;27:895–903.Langhorn R, Tarnow I, Willesen JL, Kjelgaard‐Hansen M, Skovgaard IM, Koch J. Cardiac troponin I and T as prognostic markers in cats with hypertrophic cardiomyopathy. J Vet Intern Med 2014;28:1485–1491.Langhorn R, Thawley V, Oyama MA, King LG, Machen MC, Trafny DJ, Willesen JL, Tarnow I, Kjelgaard‐Hansen M. Prediction of long-term outcome by measurement of serum concentration of cardiac troponins in critically ill dogs with systemic in?ammation. J Vet Intern Med 2014;28:1492–1497Langhorn R, Willesen JL, Tarnow I, Kjelgaard-Hansen M. Evaluation of a high-sensitivity assay for measurement of canine and feline serum cardiac troponin I. Vet Clin Pathol 2013;42:490– 498Langhorn R, Willesen JL. Cardiac Troponins in Dogs and Cats. J Vet Intern Med. 2016 Jan-Feb;30(1):36-50..LaVecchio D, Marin LM, Baumwart R, Iazbik MC, Westendorf N, Couto CG. Serum cardiac troponin I concentration in retired racing greyhounds. J Vet Intern Med 2009;23:87–90. 79. Ledsome JR, Wilson N, Courneya CA, Rankin AJ. Release of atrial natriuretic peptide by atrial distention. Can J Physiology Pharmacol 1985;63(6):739-742Linklater AKJ, Lichtenberger MK, Thamm DH, Tilley L, Kirby R. Serum concentrations of cardiac troponin I and cardiac troponin T in dogs with class IV congestive heart failure due to mitral valve disease. J Vet Emerg Crit Care 2007;17:243–249.Ljungvall I, Hoglund K, Tidholm A, Olsen LH, Borgarelli M, Venge P, H?ggstr?m J. Cardiac troponin I is associated with severity of myxomatous mitral valve disease, age, and C-reactive protein in dogs. J Vet Intern Med 2010;24:153–159.MacDonald KA, Kittleson MD, Larson RF, Kass P, Klose T, Wisner ER. The effect of ramipril on left ventricular mass, myocardial fibrosis, diastolic function, and plasma neurohormones in Maine Coon cats with familial hypertrophic cardiomyopathy without heart failure. J Vet Intern Med. 2006;20(5):1093-105.MacDonald KA, Mark D. Kittleson, Coralie Munro, Philip Kass. Brain Natriuretic Peptide Concentration in Dogs with Heart Disease and Congestive Heart Failure. J Vet Intern Med.2003;17:172–177.Machen MC, Oyama MA, Gordon SG, Rush JE, Achen SE, Stepien RL, Fox PR, Saunders AB, Cunningham SM, Lee PM, Kellihan HB. Multi-centered investigation of a point-of-care NT-proBNP ELISA assay to detect moderate to severe occult (pre-clinical) feline heart disease in cats referred for cardiac evaluation. J Vet Cardiol. 2014;16(4):245-55.Mainville CA, Clark GH, Esty KJ, Foster WM, Hanscom JL, Hebert KJ, Lyons HR. Analytical validation of an immunoassay for the quantification of N-terminal pro–B-type natriuretic peptide in feline blood. J Vet Diagn Invest. 2015;27(4):414 –42.Moonarmart W, Boswood A, Luis Fuentes V, Brodbelt D, Souttar K, Elliott J. N-terminal pro B-type natriuretic peptide and left ventricular diameter independently predict mortality in dogs with mitral valve disease. J Small Anim Pract. 2010;51:84-96.Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I, Nishino K, Yoshimasa T, Nakao K. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an emergency cardiac hormone against ventricular overload. J Clin Invest. 1995;96:1280-1287.Nakamura RK, Rishniw M, King MK, Sammarco CD. Prevalence of echocardiographic evidence of cardiac disease in apparently healthy cats with murmurs. J Feline Med Surg. 2011;13(4):266-71.O’Brien PJ, Smith DEC, Knechtel TJ, et al. Cardiac troponin I is a sensitive, speci?c biomarker of cardiac injury in laboratory animals. Lab Anim 2006;40:153–171Oyama MA, Fox PR, Rush JE, Rozanski EA, Lesser M. Clinical utility of serum N-terminal pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity. J Am Vet Med Assoc. 2008;232:1496–1503.Oyama MA, Rush JE, Rozanski EA, Fox PR, Reynolds CA, Gordon SG, Bulmer BJ, Lefbom BK, Brown BA, Lehmkuhl LB, Prosek R, Lesser MB, Kraus MS, Bossbaly MJ, Rapoport GS, Boileau JS. Assessment of serum N-terminal pro-B-type natriuretic peptide concentration for di?erentiation of congestive heart failure from primary respiratory tract disease as the cause of respiratory signs in dogs. J Am Vet Med Assoc 2009;235:1319–1325.Oyama MA, Sisson DD, Solter PF. Prospective screening for occult cardiomyopathy in dogs by measurement of plasma atrial natriuretic peptide, B-type natriuretic peptide, and cardiac troponin-I concentrations. Am J Vet Res. 2007;68:42–47.Oyama MA, Sisson DD, Solter PF. Prospective screening for occult cardiomyopathy in dogs by measurement of plasma atrial natriuretic peptide, B-type natriuretic peptide, and cardiac troponin-I concentrations. Am J Vet Res 2007; 68:42–47Oyama MA, Sisson DD. Cardiac troponin-I concentration in dogs with cardiac disease. J Vet Intern Med 2004;18:831–839.Oyama MA, Solter PF. Validation of an immunoassay for measurement of canine cardiac troponin-I. J Vet Cardiol 2004;6:17–24.Paige CF, Abbott JA, Elvinger F, Pyle RL. Prevalence of cardiomyopathy in apparently healthy cats. J Am Vet Med Assoc. 2009;234:1398-1403. Payne EE, Roberts BK, Schroeder N, Burk RL, Schermerhorn T. Assessment of a point-of-care cardiac troponin I test to di?erentiate cardiac from noncardiac causes of respiratory distress in dogs. J Vet Emerg Crit Care 2011;21:217–225.Pelander L, H?ggstr?mm, Ley CJ, Ljungvall I. Cardiac troponin I and amino-terminal pro B-type natriuretic peptide in dogs with stable chronic kidney disease. J Vet Intern Med. 2017; 31:805-13.Pierce KV, Rush JE, Freeman LM, Cunningham SM, Yang VK. Association between Survival Time and Changes in NT-proBNP in Cats Treated for Congestive Heart Failure. J Vet Intern Med. 2017;31:678–684.Polizopoulou ZS, Koutinas CK, Dasopoulou A, Patsikas M, York M, Roman I, Gandhi M, Patel S, Koutinas AF, O'Brien PJ. Serial analysis of serum cardiac troponin I changes and correlation with clinical ?ndings in 46 dogs with mitral valve disease. Vet Clin Pathol 2014;43:218–225Porciello F, Rishniw M, Herndon WE, Birettoni F, Antognoni MT, Simpson KW. Cardiac troponin I is elevated in dogs and cats with azotaemia renal failure and in dogs with non-cardiac systemic disease. Aust Vet J 2008;86:390–394.Potter LR. Natriuretic peptide metabolism, clearance and degradation. FEBS J. 2011,;278(11):1808–1817.Pro?ek R and Ettinger SJ. 2010. Biomarkers of Cardiovascular Disease. In: Ettinger SJ and Feldman E, editors. Textbook of Veterinary Internal Medicine Expert Consult. 7th Edition. St. Louis (MO): Saunders Elsevier. p. 1187-1196. Prosek R, Sisson DD, Oyama MA, Solte PF. Distinguishing Cardiac and Noncardiac Dyspnea in 48 Dogs Using Plasma Atrial Natriuretic Factor, B-Type Natriuretic Factor, Endothelin, and Cardiac Troponin-I. J Vet Intern Med. 2007;21(2):238-42.Raffan E, Loureiro J, Dukes‐McEwan J, Fonfara S, James R, Swift S, Bexfield N, Herrtage ME, Archer J. The Cardiac Biomarker NT‐proBNP Is Increased in Dogs with Azotemia. J Vet Intern Med. 2009;23(6):1184-9.Reynolds CA, Brown DC, Rush JE, Fox PR, Nguyenba TP, Lehmkuhl LB, Gordon SG, Kellihan HB, Stepien RL, Lefbom BK, Meier CK, Oyama MA. Prediction of first onset of congestive heart failure in dogs with degenerative mitral valve disease: the PREDICT cohort study. J Vet Cardiol.2012;14(1):193-202. Sangster JK, Panciera DL, Abbott JA, Zimmerman KC, Lantis AC. Cardiac biomarkers in hyperthyroid cats. J Vet Intern Med 2014;28:465-472.Schmidt MK, Reynolds CA, Estrada AH, Prosek R, Maisenbacher HW, Sleeper MM, Oyama MA. Effect of azotemia on serum N‐terminal proBNP concentration in dogs with normal cardiac function: A pilot study. J Vet Cardiol 2009;11:S81–S86.Schober KE, Cornand C, Kirbach B, Aupperle H, Oechtering G. Serum cardiac troponin I and cardiac troponin T concentrations in dogs with gastric dilatation-volvulus. J Am Vet Med Assoc 2002;221:381– 388.Schober KE, Hart TM, Stern JA, Li X, Samii VF, Zekas LJ, Scansen BA, Bonagura JD. Effects of treatment on respiratory rate, serum natriuretic peptide concentration, and Doppler echocardiographic indices of left ventricular filling pressure in dogs with congestive heart failure secondary to degenerative mitral valve disease and dilated cardiomyopathy. J Am Vet Med Assoc. 2011;15;239(4):468-79.Schober KE, Kirbach B, Oechtering G. Noninvasive assessment of myocardial cell injury in dogs with suspected cardiac contusion. J Vet Cardiol 1999;1:17–25.Serres F, Pouchelon JL, Poujol L, Lefebvre HP, Trumel C, Daste T, Sampedrano CC, Gouni V, Tissier R, Hawa G, Chetboul V. Plasma N-terminal pro-B-type natriuretic peptide concentration helps to predict survival in dogs with symptomatic degenerative mitral valve disease regardless of and in combination with the initial clinical status at admission. J Vet Cardiol. 2009;11:103-121. Sharkey LC, Berzina I, Ferasin L, Tobias AH, Lulich JP, Hegstad-Davies RL. Evaluation of serum cardiac troponin I concentration in dogs with renal failure. J Am Vet Med Assoc 2009;234:767–770. Shaw SP, Rozanski EA, Rush JE. Cardiac troponins I and T in dogs with pericardial e?usion. J Vet Intern Med 2004;18:322– 324.Singletary GE, Morris NA, Lynne O’Sullivan M, Gordon SG, Oyama MA. Prospective evaluation of NT-proBNP assay to detect occult dilated cardiomyopathy and predict survival in Doberman Pinschers. J Vet Intern Med 2012;26: 1330-6.Sj?strand K, Wess G, Ljungvall I, H?ggstr?m J, Merveille AC, Wiberg M, Gouni V, Lundgren Willesen J, Han?s S, Lequarré AS, Mejer S?rensen L, Wolf J, Tiret L, Kierczak M, Forsberg S, McEntee K, Battaille G, Sepp?l? E, Lindblad-Toh K, Georges M, Lohi H, Chetboul V, Fredholm M, H?glund K. Differences in Natriuretic Peptides in Healthy Dogs. J Vet Intern Med. 2014;28:451-457.Spratt D, Mellanby R, Drury N, Archer J. Cardiac troponin I: evaluation of a biomarker for the diagnosis of heart disease in the dog. J Small Anim Pract 2005;46:139–145.Suga S, Nakao K, Hosoda K, Mukoyama M, Ogawa Y, Shirakami G, Arai H, Saito Y, Kambayashi Y, Inouye K. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology.?1992;130(1):229-39.Tarducci A, Abate O, Borgarelli M, et al. Serum values of cardiac troponin-T in normal and cardiomyopathic dogs. Vet Res Commun 2004;28:385–388. Thomas CJ, Woods RL. Haemodynamic action of B‐type natriuretic peptide substantially outlasts its plasma half‐life in conscious dogs. Clin Exp Pharmacol Physiol. 2003;30:369–375.Wagner T, Fuentes VL, Payne JR, McDermott N, Brodbelt D. Comparison of auscultatory and echocardiographic findings in healthy adult cats. J Vet Cardiol. 2010;12:171-182. Wells SM, Shofer FS, Walters PC, Stamoulis ME, Cole SG, Sleeper MM. Evaluation of blood cardiac troponin I concentrations obtained with a cage-side analyzer to di?erentiate cats with cardiac and noncardiac causes of dyspnea. J Am Vet Med Assoc 2014;244:425–430.Wess G, Butz V, Mahling M, Hartmann K. Evaluation of N terminal pro-B-type natriuretic peptide as a diagnostic marker of various stages of cardiomyopathy in Doberman Pinschers. Am J Vet Res 2011;72:642-9.Wess G, Daisenberger P, Hirschberger J and Hartmann K. The utility of NT-proBNP to differentiate cardiac and respiratory causes of dyspnea in cats [Abstract]. Journal of Veterinary Internal Medicine. 2008;22:707-708.Wess G, Domenech O, Dukes-McEwan J, H?ggstr?m J, Gordon S. European Society of Veterinary Cardiology screening guidelines for dilated cardiomyopathy in Doberman Pinschers. J Vet Cardiol. 2017;19:405-415.Wess G, Simak J, Mahling M, Hartmann K. Cardiac troponin I in doberman pinschers with cardiomyopathy. J Vet Intern Med 2010;24:843–849.Winter RL, Saunders AB, Gordon SG, Buch JS, Miller MW. Biologic variability of N-terminal pro-brain natriuretic peptide in healthy dogs and dogs with myxomatous mitral valve disease. J Vet Cardiol. 2017;19(2):124-131.Wolf J, Gerlach N, Weber K, Klima A, Wess G. Lowered N-terminal pro-B-type natriuretic peptide levels in response to treatment predict survival in dogs with symptomatic mitral valve disease. J Vet Cardiol. 2012;14:399-408.Table 1. Cut-off values recommend by IDEXX using the Canine and Feline Cardiopet? proBNP Assay IDEXX Laboratories Inc., Westbrook, Maine, USA.For Dogs Suspected of Heart Disease (murmur or at risk breed)<900 pmol/lNot compatible with increased stretch and stress on the myocardium. Clinically significant heart disease is unlikely at this time.>900 pmol/lCompatible with increased stretch and stress on the myocardium. Clinically significant heart disease is likely. Additional diagnostics are recommended to diagnose and assess severity of the disease.> 735 pmol/l (Doberman)Increased risk of dilated cardiomyopathy. >1500pmol/l(<20kg with MMVD)Increased risk of heart failure in the coming 12 months. Thoracic radiographs and vertebral heart score, at a minimum, are required.For Dogs with a Murmur and Clinical Signs Consistent with Cardiac Disease<900 pmol/lLikelihood that clinical signs (respiratory and/or exercise intolerance) are due to heart failure is low. 900-1800pmol/lIncreased stretch and stress on the myocardium. However, results in this range do not allow reliable differentiation between clinical signs due to heart failure versus those from other causes. Additional diagnostics are recommended.>1800pmol/lIncreased stretch and stress on the myocardium. The likelihood that clinical signs (i.e. respiratory and/or exercise intolerance) are due to heart failure is high. Additional diagnostics are recommended to diagnose and assess severity of the disease.Recommendations for cats<100 pmol/lClinically significant cardiomyopathy is unlikely100-270 pmol/lClinically significant cardiomyopathy is unlikely but early disease may be present. Consider repeating NT-proBNP in 3-6 months or an echocardiogram. >270 pmol/lClinically significant CM is highly likely. Further cardiac work-up including an echo is recommended.Figure 1. Cardiac troponin complexFigure 2. VetScan i-STAT? 1 Handheld Analyzer and VetScan i-STAT? Cardiac Troponin I (cTnI) cartridge, Abaxis, Union City, CA. ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download